Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct

By K. Conway, J. Rochet, R. Bieganski, P. Lansbury. Science, 2001

895 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/f3bd196f41bc2337bee4e6dcdf7ab0c84a44aff5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

Citations in the corpus

α-Synuclein in Parkinson's disease. (2012, background): “Iron and dopamine appear to exert a similar effect, although whether this is a direct interaction or mediated by oxidation is less clear (OstrerovaGolts et al. 2000; Conway et al. 2001; Kostka et al. 2008; Leong et al. 2009).”
Parkinson's Disease Mechanisms and Models (2003, background): “Furthermore, the selective vulnerability of dopaminergic neurons in PD may derive from the ability of DAfunction, possibly by regulating the rate of cycling of the readily releasable pool (Abeliovich et al., 2000). itself to stabilize these noxious -synuclein protofibrils (Conway et al., 2001).”
Cell-Produced α-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival (2010, background): “…function of -synuclein is not understood, although there is evidence that abnormal folding and aggregation may play a role and that the toxic -synuclein species may be oligomeric intermediates (Conway et al., 2000, 2001; Goldberg and Lansbury, 2000; Olanow et al., 2004; Vekrellis et al., 2004).”
Molecular pathophysiology of Parkinson's disease. (2005, background): “Catecholamines, particularly dopamine, can react with α-synuclein to form covalent adducts that slow conversion of protofibrils to fibrils (Conway et al. 2001), thus promoting protofibril accumulation.”
Plant phenolic antioxidant and prooxidant activities: phenolics-induced oxidative damage mediated by metals in plants. (2002, background): “Growing evidence indicates that the catecholamine neurotransmitter dopamine, when oxidized, can act as a direct causative agent of Parkinson disease neurodegeneration (Conway et al., 2001; Stokes et al., 1999).”
A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis (2002, background): “…are neurotoxic (Graham, 1978; Hastings et al., 1996; Stokes et al., 1999; Lotharius and O’Malley, 2000), -synuclein itself is modified by DA quinone (Conway et al., 2001), and DA release is enhanced in mice lacking -synuclein expression as measured by paired-pulse stimulation (Abeliovich et al.,…”